Hyperinsulinemia induces insulin resistance and immune suppression via Ptpn6/Shp1 in zebrafish

Rubén Marín-Juez, Susanne Jong-Raadsen, Shuxin Yang[1] and Herman P Spaink[1]

ZF-Screens BV, J.H. Oortweg 19, 2333 CH Leiden, The Netherlands
[1]Institute of Biology, Leiden University, Einsteinweg 55, 2333 CC Leiden, The Netherlands

Correspondence
should be addressed
to R Marín-Juez or H P Spaink
Emails
marinjuez@zfscreens.com or
h.p.spaink@biology.
leidenuniv.nl

Abstract

Type 2 diabetes, obesity, and metabolic syndrome are pathologies where insulin resistance plays a central role, and that affect a large population worldwide. These pathologies are usually associated with a dysregulation of insulin secretion leading to a chronic exposure of the tissues to high insulin levels (i.e. hyperinsulinemia), which diminishes the concentration of key downstream elements, causing insulin resistance. The complexity of the study of insulin resistance arises from the heterogeneity of the metabolic states where it is observed. To contribute to the understanding of the mechanisms triggering insulin resistance, we have developed a zebrafish model to study insulin metabolism and its associated disorders. Zebrafish larvae appeared to be sensitive to human recombinant insulin, becoming insulin-resistant when exposed to a high dose of the hormone. Moreover RNA-seq-based transcriptomic profiling of these larvae revealed a strong downregulation of a number of immune-relevant genes as a consequence of the exposure to hyperinsulinemia. Interestingly, as an exception, the negative immune modulator protein tyrosine phosphatase nonreceptor type 6 (*ptpn6*) appeared to be upregulated in insulin-resistant larvae. Knockdown of *ptpn6* was found to counteract the observed downregulation of the immune system and insulin signaling pathway caused by hyperinsulinemia. These results indicate that *ptpn6* is a mediator of the metabolic switch between insulin-sensitive and insulin-resistant states. Our zebrafish model for hyperinsulinemia has therefore demonstrated its suitability for discovery of novel regulators of insulin resistance. In addition, our data will be very useful in further studies of the function of immunological determinants in a non-obese model system.

Introduction

Metabolic disorders (e.g. diabetes, obesity, and metabolic syndrome) have over the past three decades reached pandemic dimensions, affecting a large number of the world population (Wild & Byrne 2006, Lin & Sun 2010). Insulin resistance is a common aspect of a number of these metabolic pathologies, such as type 2 diabetes, and also a powerful parameter for predicting the incidence of cardio-vascular diseases and cancer (Shanik *et al.* 2008). Hyperinsulinemia is the hallmark of insulin resistance in mammals. For instance, a twofold increase in plasma insulin levels can induce insulin resistance in mice, resembling the pattern in insulin-resistant patients with pathological obesity or type 2

Published by Bioscientifica Ltd.

diabetes who show similar increases in insulin levels (Shanik *et al.* 2008). As insulin resistance is common to a number of metabolic diseases of which the relationships are still poorly understood, it is difficult to study with respect to causal relationships and genetic factors that are involved. Current models used for the study of insulin resistance range from mutant rodents to obese monkeys (Shafrir 2010). Although these models reproduce the human situation with regard to obesity and insulin resistance, there still appear to be many conflicting results compared with the human situation, mainly due to the heterogeneity of the metabolic states where insulin resistance is observed (Harano *et al.* 2002, Kahn 2003, Steinberger & Daniels 2003).

The zebrafish (*Danio rerio*) is emerging as a model for deciphering the mechanisms underlying pathologies caused by an altered metabolism (Seth *et al.* 2013). Principles of energy expenditure and metabolism are evolutionarily conserved in metazoans (Schlegel & Stainier 2007). In addition, zebrafish larvae at 4 days post fertilization (dpf) have developed many functional organs (Elo *et al.* 2007), with the advantages inherent to the zebrafish larvae system as presented in many review papers (Lieschke & Currie 2007, Ali *et al.* 2011, Liu & Leach 2011, Meijer & Spaink 2011, Santoriello & Zon 2012, Driessen *et al.* 2013, Seth *et al.* 2013). We therefore set out to develop a non-obese zebrafish model for the study of insulin metabolism and its associated disorders. In this study, we report on the finding that 4 dpf zebrafish larvae are sensitive to human insulin and become insulin-resistant when treated with high doses of insulin. Moreover, by profiling the transcriptomic response of insulin-sensitive and insulin-resistant larvae, we further characterize the effects of hyperinsulinemia on the metabolism. At the transcriptome level, we observed a general downregulation of immune-relevant genes potentially mediated by protein tyrosine phosphatase nonreceptor type 6 (*ptpn6*).

PTPN6 (also known as SHP1) is expressed mainly in hematopoietic cells (Yi *et al.* 1992) and has been described as an important negative regulator of immune signaling pathways (An *et al.* 2008, Croker *et al.* 2008). In addition, it has been reported that PTPN6 may be involved in the development of insulin resistance and non-alcoholic fatty liver diseases in obesity (Xu *et al.* 2012, 2014*a*). Pioneering studies performed by Dubois *et al.* (2006) showed that PTPN6-deficient mice exhibited improved insulin sensitivity and glucose tolerance. Further studies by this group demonstrated that hepatocyte-specific *Ptpn6* knockout (*Ptpn6*[H-KO]) mice were protected from hepatic insulin resistance and hepatocellular damage caused by diet-induced obesity (Xu *et al.* 2012, 2014*a*).

In this study, we made use of a previously described test system for Ptpn6 function in zebrafish, using reverse genetic approaches (Kanwal *et al.* 2013). We showed that knockdown of *ptpn6* in zebrafish larvae interferes with the effects caused by hyperinsulinemia. In conclusion, using this non-obese vertebrate model, we were able to demonstrate that *ptpn6* expression is stimulated by hyperinsulinemia, and that *ptpn6* knockdown regulates key elements of the insulin pathway and also the leptin signaling pathway.

Materials and methods

Fish maintenance

WT zebrafish of the AB/TL strain were handled in compliance with the Local Animal Welfare legislation and maintained as described previously (Kimmel *et al.* 1995, Westerfield 2000). Embryos were grown at 28.5 °C in egg water (60 μg/ml Ocean Salts). During PBS/insulin injections, fish were kept under anesthesia in egg water containing 0.02% buffered 3-aminobenzoic acid ethyl ester (Sigma–Aldrich).

Morpholino injections

For knockdown of *ptpn6*, a morpholino oligonucleotide (Gene Tools, LLC, Philomath, OR, USA) targeting *ptpn6*, kindly donated by Dr A H Meijer, was injected (Kanwal *et al.* 2013). The morpholino (5′-ACTCATTCCTTACCC-GATGCGGAGC-3′) was diluted to a concentration of 0.08 mM in 1× Danieau's buffer (58 mM NaCl, 0.7 mM KCl, 0.4 mM $MgSO_4$, 0.6 mM $Ca(NO_3)_2$, and 5.0 mM HEPES (pH 7.6)) and 1 nl was injected at the one-cell stage using a Femtojet injector (Eppendorf, Hamburg, Germany). Specificity of the morpholino was confirmed phenotypically and by RT-PCR (Supplementary Fig. 1, see section on supplementary data given at the end of this article).

Insulin injections

To inject PBS and human recombinant insulin (Sigma–Aldrich), 1 nl was injected into the caudal aorta of 4 dpf zebrafish larvae using a glass capillary (Supplementary Fig. 2, see section on supplementary data given at the end of this article).

qPCR analysis

RNA was isolated using TRIzol (Life Technologies). RNA samples were treated with RQ1 DNAse (Promega) and reverse

transcribed using the iScript cDNA Synthesis Kit (Bio-Rad Laboratories B.V.), according to the manufacturers' protocols. For the quantification of mRNA expression, qPCR was carried out using iQ SYBR Green Supermix (Bio-Rad Laboratories B.V.). The reactions were run in a iCycler Thermal Cycler (Bio-Rad Laboratories B.V.) under the following conditions: 2 min at 50 °C, 8 min at 95 °C, followed by 40 cycles of 15 s denaturation at 95 °C and 30 s at the corresponding melting temperatures, and a final melting curve of 81 cycles from 55 to 95 °C (0.5 °C increments for every 10 s). mRNA expression levels were normalized against the expression of *ppial* as a housekeeping gene. Primer sequences are presented in Supplementary Table 7, see section on supplementary data given at the end of this article.

Glucose measurements

Glucose measurements were done using a fluorescence-based enzymatic detection kit (Biovision, Inc., Mountain View, CA, USA) as described previously (Jurczyk *et al.* 2011).

RNA deep sequencing (RNA-seq)

Ten larvae per condition were homogenized in 1 ml of TRIzol reagent (Life Technologies), and total RNA was extracted according to the manufacturer's instructions. RNA samples were treated with DNaseI (Life Technologies) to remove residual genomic DNA. RNA integrity was analyzed by Lab-on-a-chip analysis (Agilent, Amstelveen, The Netherlands). The average RNA integrity (RIN) value of the RNA samples was 9.7, with a minimum of 9.5. A total of 2 μg of RNA was used to make RNA-seq libraries using the Illumina TruSeq RNA Sample Preparation Kit v2 (Illumina, Inc., San Diego, CA, USA). The manufacturer's instructions were followed with the exception of two modifications. In the adapter ligation step, 1 μl, instead of 2.5 μl, adaptor was used. In the library size-selection step, the library fragments were isolated with a double Ampure XP purification with a 0.7× beads to library ratio (Beckman Coulter, Woerden, The Netherlands). The resulting mRNA-seq library was sequenced using an Illumina HiSeq2500 Instrument (Illumina, Inc.) according to the manufacturer's instructions with a read length of 2×50 nucleotides. Image analysis and base-calling were done by the Illumina HCS version 2.0.12. Data analysis was performed using Genetiles Software (www.genetiles.com, W J Veneman, J de Sonneville, K J van der Kolk, A Ordas, Z Al-Ars, A H Meijer and H P Spaink 2014, unpublished). False discovery rate (FDR)-adjusted *P* values were calculated based on the algorithm of Benjamini & Hochberg (1995). The raw RNA-seq data have been deposited in the NCBI GEO database under accession number GSE55836.

Western blot analysis

Whole, homogenized zebrafish larvae were prepared in lysis buffer ($n=15$/sample; 25 mM Tris–HCl (pH 7.6), 150 mM NaCl, 1% NP-40, 1% sodium-deoxycholate, and 0.1% SDS) with protease inhibitor (Roche Applied Sciences). The lysates were centrifuged at 12 000 *g* for 10 min at 4 °C and supernatants stored. Supernatants were incubated at 95 °C for 10 min. The protein concentration was determined using a BCA Protein Assay Kit (Thermo Scientific, Rockford, IL, USA). The extracted protein samples were subjected to SDS–PAGE and transferred onto nitrocellulose membranes (Bio-Rad). The membranes were blocked with 3% BSA in Tris-buffered saline with 0.1% Tween 20 for 1 h at room temperature. The membranes were then incubated with antibodies recognizing phosphorylated AKT (Cell Signaling Technology, Beverly, MA, USA; no. 9271, phospho-Akt Ser 473), total AKT (Cell Signaling, no. 9272), and Pan-actin (Cell Signaling, no. 4968) as a loading control overnight. After washing with Tris-buffered saline with 0.1% Tween 20, the membranes were incubated with the appropriate HRP-conjugated secondary antibodies (GE Healthcare, Chalfont St Giles UK) for 1 h and washed again. Immunoreactivity was detected by chemiluminescence (GE Healthcare). Finally, the bands were quantified by densitometry using ImageJ Software (National Institutes of Health, Bethesda, MD, USA). The bands were quantified by densitometry using ImageJ 64 Software (National Institutes of Health).

Results

Zebrafish that received human insulin showed inhibition of gluconeogenesis and transient hypoglycemia

In order to study whether zebrafish are sensitive to human insulin, we analyzed phosphoenolpyruvate carboxykinase 1 (*pck1*) expression levels because the transcription of this gene is well known to be inhibited by insulin (O'Brien & Granner 1990). For instance in mammalian systems, *pck1* RNA levels are decreased after 20–40 min of insulin stimulation (Sasaki *et al.* 1984, O'Brien & Granner 1990). Zebrafish larvae at 4 dpf received injections of 1 nl of 100 nM human recombinant insulin into the caudal aorta (Supplementary Fig. 2A). qPCR analysis of *pck1* expression was carried out in zebrafish larvae 0.5, 1, 2, and 4 h after injection (hpi) (Fig. 1A). The observed results confirmed that *pck1* expression was significantly reduced in the presence of insulin at all the time points

Figure 1

Zebrafish larvae are sensitive to human insulin. (A) Outline of the experiment. Zebrafish larvae received injections of 100 nM human recombinant insulin into the caudal aorta at 4 dpf. Control larvae received injections of PBS. Samples for glucose measurements were taken 0, 15, 30, 45, 60, 120, and 240 min after injection. The samples for qPCR analysis were taken at 0.5, 1, 2, and 4 hpi. Values on the scale are in minutes. (B) Expression of *pck1* was analyzed by qPCR 0.5, 1, 2, and 4 hpi. RNA was extracted from larvae that had received injections of PBS or 100 nM insulin.

Data (mean ± s.e.m.) are combined from four biological replicates ($n = 10$ larvae/group) and expressed relative to their respective PBS control, which is defined as 1. (C) Glucose dynamics were studied from 0 to 240 min after 100 nM insulin administration and compared with results for larvae that received injections of PBS. Data (mean ± s.e.m.) are combined from five biological replicates ($n = 10$ larvae/group). *$P < 0.05$, **$P < 0.01$, and ***$P < 0.001$. A full colour version of this figure is available at http://dx.doi.org/10.1530/JOE-14-0178.

studied (Fig. 1B). Next, to further confirm if insulin injection exerts the hypoglycemic effect observed in mammals, we carried out a time course experiment for measuring glucose levels of zebrafish larvae that received injections of insulin (Fig. 1A). Our results showed that, as in mammals, insulin administration leads to a fast reduction in free glucose levels from 15 to 45 min post injection, restoring normoglycemia from 2 hpi and onwards (Fig. 1C). Unfortunately, we failed to detect significant changes in Akt phosphorylation on the residue S473 30 min after injection, probably due to the fact that the analysis was performed at a whole-embryo level losing in this way sensitivity (Supplementary Fig. 2B).

Zebrafish larvae treated with a high dose of human insulin develop insulin resistance

The prolonged downregulation observed in *pck1* expression, up to 4 hpi, together with the fact that larvae injected with

100 nM insulin may experience supra-physiological concentrations of the hormone, led us to propose the hypothesis that the larvae that received injections of insulin may be developing hyperinsulinemia-derived insulin resistance. To test this hypothesis, zebrafish larvae were administered human insulin as described earlier and at 4 hpi the same larvae received a second dose of insulin (Fig. 2A), while control individuals received injections of PBS at the same time points. Interestingly, after the injection of the second dose of insulin, zebrafish larvae exhibited transient hyperglycemia rather than the expected hypoglycemia (Fig. 2B). In addition, to confirm whether this is a dose-dependent effect, we carried out qPCR analysis of *pck1* expression of larvae that had received injections of 1 nl of 10 nM, 100 nM, or 1 μM human insulin at 4 hpi. Our results indicated that at 10 nM, *pck1* expression was not significantly reduced compared with results for control embryos, while embryos that received injections of 100 nM and 1 μM insulin

Figure 2

Zebrafish larvae treated with a high dose of insulin lose insulin sensitivity. (A) Outline of the experiment. Zebrafish larvae received injections of 100 nM human recombinant insulin into the caudal aorta at 4 dpf and a second injection 4 hpi (240 min). Control larvae received injections of PBS. Samples for glucose measurements were taken 0, 15, 30, and 240 min after the first injection and 30 and 120 min after the second injection. Values on the scale are in minutes. (B) Glucose dynamics were studied 0, 15, 30, and 240 min after administration of 100 nM insulin to confirm the effect of the first injection. A second injection with the same dose of insulin was performed 240 min after the first dose and glucose levels were analyzed 30 and 120 min later.

Larvae that had received injections of PBS were used as controls and exhibited no significant changes in glucose levels during the experiment. Data (mean$\pm$s.e.m.) are combined from four biological replicates ($n=5$ larvae/group). (C) Western blotting analysis of whole larvae at 4 hpi of PBS or 100 nM insulin was carried out as indicated in 'Materials and methods' section. Data (mean$\pm$s.e.m.) are combined from four biological replicates ($n=15$ larvae/group) and expressed relative to their respective PBS control, which is defined as 1 (i). A picture of a representative immunoblot is shown (ii). *$P<0.05$ and **$P<0.01$. A full colour version of this figure is available at http://dx.doi.org/10.1530/JOE-14-0178.

presented a significant downregulation of *pck1* expression (Supplementary Fig. 3, see section on supplementary data given at the end of this article).

Next, to further confirm that zebrafish larvae at 4 hpi experienced insulin resistance, we analyzed Akt activity by measuring phosphorylation levels on residue S473. In agreement with the previous observations, larvae that received injections of 100 nM insulin at 4 hpi exhibited a significant reduction in Akt phosphorylation (Fig. 2C).

Overall, these results indicate that administration of high doses of human insulin to zebrafish larvae results in a loss of insulin sensitivity.

Transcriptomic profiling shows that key genes for the insulin metabolism and immune system are downregulated in hyperinsulinemic zebrafish larvae

To better characterize how the shift from an insulin-sensitive state to an insulin-resistant state may affect zebrafish larvae, we carried out an RNA-seq-based transcriptome analysis of zebrafish larvae that received injections of insulin at 0.5 and

4 hpi (Fig. 3A). Larvae that received injections of PBS were used as controls and RNA was isolated from ten individuals per condition. To analyze the data, we used significance cutoffs at 1.5-fold change at $P<0.05$ (FDR adjusted P value). As expected, samples at 0.5 hpi showed a reduced number of differentially expressed genes (DEGs) compared with samples at 4 hpi, with 630 (202 upregulated and 428 downregulated) and 4187 (1639 upregulated and 2548 downregulated) DEGs respectively. Next, to further study the annotated DEGs at 0.5 and 4 hpi, we carried out a gene ontology (GO) analysis for functional classification (Supplementary Tables 1 and 2, see section on supplementary data given at the end of this article). Study of GO biological processes at 0.5 hpi revealed a significant enrichment in functional categories involved in metabolism (e.g. response to hormone, response to nutrient levels, gluconeogenesis, and glucose metabolic process), ion transport (e.g. potassium ion transport and monovalent inorganic cation transport), lipid biosynthetic process, and rhythmic process (Fig. 3). Analysis of GO-biological process at 4 hpi showed enrichment in categories related to carbohydrate/insulin

Journal of Endocrinology

Figure 3

Transcriptome analysis and comparison of zebrafish larvae in an insulin-sensitive state and insulin-resistant state. Zebrafish larvae received injections of 100 nM human recombinant insulin at into the caudal aorta at 4 dpf. Control larvae received injections of PBS. RNA-seq was carried out on RNA samples extracted from pools of ten larvae per condition and a total of four samples per condition were analyzed. Significance cutoffs were set at fold change >|1.5| and $P < 0.05$. Venn diagrams show the overlap between DEGs after 0.5 and 4 hpi. The number of DEG is indicated in the Venn diagrams and selected GO terms for biological processes are indicated next to the appropriate condition. A detailed overview of the data is shown in Supplementary Tables 1–7. A full colour version of this figure is available at http://dx.doi.org/10.1530/JOE-14-0178.

metabolism (e.g. response to insulin stimulus, positive regulation of glucose import, and response to nutrient levels), innate immune response (e.g. regulation of cytokine production and upregulation of innate immune response), organ development (e.g. sensory organ development and embryonic skeletal system development), fatty acid metabolic process, digestive system process, and transmembrane transport (Fig. 3).

Interestingly, larvae at 4 hpi showed downregulation of insulin metabolism, confirming our previous observations, and also appeared to experience a general downregulation of immune-related processes (Fig. 3). Among DEGs involved in the insulin signaling pathway, all the genes known to play a central role in this pathway (*insr*, *irs1*, *irs2*, *pik3cb*, and *pdk1*) appeared to be downregulated at 4 hpi (Fig. 4). In addition, to further understand the effects on the innate immune system, we analyzed the expression of genes

coding for important cytokines and for signal mediators and transcription regulators previously demonstrated to be relevant to the immune response (van der Vaart *et al*. 2012, Meijer *et al*. 2014). Strikingly, our data showed that all the genes studied in this context were downregulated at 4 hpi, except *ptpn6*, *cxcr3.1*, *cxcr4b*, and *irf5* (Fig. 4). Furthermore, other genes known to have a relevant role during the defense response in zebrafish showed similar effects (Fig. 4). Finally, we also studied genes important for various metabolic processes: genes involved in the leptin signaling pathway, gluconeogenesis and lipid metabolism. Overall, the observed effect on the expression of these genes confirmed the effect of insulin at 0.5 hpi, for instance on *per2* and *pck1* which are known to be rapidly regulated by insulin in mammals (O'Brien & Granner 1990, Tahara *et al*. 2011). The data also provide further evidence of the loss of insulin sensitivity at 4 hpi, as observed with *lepb*, *lepr*, *gck*,

Figure 4

Transcriptomic profile of the switch from an insulin-sensitive state to an insulin-resistant state confirms the downregulation of insulin and leptin signaling pathways and reveals strong downregulation of immune-relevant genes. For each gene, the left box corresponds to the changes observed at 0.5 hpi and the right indicates changes observed at 4 hpi. Blue boxes represent downregulation, yellow boxes represent upregulation, and grey boxes indicate that no significant changes were observed. Significance cutoffs were set at fold change (FC) >|1.5| and $P < 0.05$. A full colour version of this figure is available at http://dx.doi.org/10.1530/JOE-14-0178.

and *dpp4* reported to be dysregulated in insulin-resistant states (Wang *et al*. 2001, Jiang *et al*. 2011, Sell *et al*. 2013). In addition, the expression of *il1b*, *cxcl-c1c*, *lepb*, *lepr*, and *pck1* was analyzed by qPCR to validate the RNA-seq data, the same effects on the expression of all the analyzed genes were detected by both techniques at 4 hpi of insulin (Supplementary Fig. 4, see section on supplementary data given at the end of this article).

Altogether, our data indicate that administration of a high dose of insulin inactivates the transcription of genes of importance for the immune system and downregulates the insulin signaling pathway and other metabolic genes. Therefore these results resemble gene expression patterns observed in insulin-resistant states in mammalian models (Ginsberg *et al*. 1976, Martin *et al*. 1983, Araki *et al*. 1994, Tamemoto *et al*. 1994, Patti & Kahn 1996, Withers *et al*. 1998, Boura-Halfon & Zick 2009).

Knockdown of *ptpn6* prevents the downregulation of insulin and leptin signaling pathways and immune-relevant genes in hyperinsulinemic larvae

One of the interesting observations from our transcriptomic profiling was that, despite the general immune suppression observed at the gene expression level, one of the few genes significantly upregulated at 4 hpi was *ptpn6*. This gene is a well-known immune modulator playing a critical role as a negative regulator of the immune response (An *et al*. 2008, Croker *et al*. 2008). Importantly, PTPN6 has been described as a modulator of insulin signaling (Dubois *et al*. 2006), and recent findings have demonstrated its importance in the development of insulin resistance and non-alcoholic fatty liver diseases in diet-induced obesity (Xu *et al*. 2014*a,b*). Recently, Kanwal *et al*. (2013) have described a zebrafish model for *ptpn6* deficiency, in which

Journal of Endocrinology

Figure 5

ptpn6 abrogation interferes with the transcriptional effect of the hyper-insulinemia. (A) Outline of the experiment. Zebrafish larvae at the one-cell stage received injections of *ptpn6* MO and morphant larvae at 4 dpf received injections of 100 nM human insulin or PBS for the controls. Expression of pro-inflammatory genes (B) and genes of the leptin and insulin signaling pathways (C) in *ptpn6* morphants was analyzed by qPCR at 4 hpi. RNA was extracted from larvae that had received injections of PBS or 100 nM insulin. Data (mean±s.e.m.) are combined from four biological replicates (*n*=5 larvae/group) and expressed relative to their respective PBS control, which is defined as 1. *P<0.05. NS, no significant differences. A full colour version of this figure is available at http://dx.doi.org/10.1530/JOE-14-0178.

they observed that abrogation of this gene causes hyperactivation of the innate immune system, indicating that the piscine ortholog of *ptpn6* may play the same role as its mammalian counterpart. In view of this, we proposed the hypothesis that long exposure to high plasma levels of insulin may stimulate *ptpn6* expression, which in turn led to a dampening of the immune system and, at least partially, to the observed insulin-resistant phenotype. To test this hypothesis, we injected 100 nM insulin intravenously at 4 dpf in larvae that had previously received injections of the *ptpn6* morpholino (Fig. 5A) which has been recently shown to efficiently abrogate *ptpn6* expression (Kanwal *et al.* 2013).

At 4 hpi we analyzed (by qPCR) RNA expression of immune relevant genes, such as *myd88*, *traf6*, *relb*, *nfkb2*, *il1b*, *cxcl-c1c*, *atf3*, and *mfap4*, as well as genes important for leptin and insulin signaling pathways, namely *lepb*, *lepr*, *insr*, *irs1*, and *irs2*. Our results (Fig. 5B) show that the immune genes analyzed were not affected by insulin in the *ptpn6*-deficient larvae, except in the case of *il1b* and *mfap4* where the same effects as detected by RNA-seq from WT larvae was observed. In addition, our data indicates that *ptpn6* abrogation prevents the downregulation of all the metabolic genes analyzed, while the expression of *lepr*, *insrb*, and *irs1* was significantly increased (Fig. 5C). Moreover, analysis of basal expression levels of *il1b*, *cxcl-clc*, *lepb*, and *lepr* in *ptpn6* morphants showed that *il1b* and *lepr* basal expression levels were similar to those of control embryos, while *lepb* and *cxcl-c1c* appeared to be significantly higher (Supplementary Fig. 5, see section on supplementary data given at the end of this article). We cannot exclude the possibility that the *ptpn6* abrogation may prevent insulin resistance and immune suppression due to a basal overexpression of some genes (e.g. *lepb* and *cxcl-clc*). Future in-depth studies would be needed to address this complex question.

Interestingly, a time course experiment (Fig. 6A) demonstrated that *ptpn6* upregulation was not observed at earlier time points (Fig. 6B). Next, to further study whether *ptpn6* morphants exhibit improved insulin sensitivity, we injected a second dose of insulin 4 hpi of the first dose and glucose levels were measured (Fig. 6A). Our results indicated that *ptpn6* morphants presented a

Published by Bioscientifica Ltd.

Figure 6

ptpn6 abrogation prevents the loss of insulin sensitivity caused by the hyperinsulinemia. (A) Outline of the experiment. Zebrafish larvae received injections of *ptpn6* MO at the one-cell stage and morphant larvae at 4 dpf received injections of 100 nM human insulin or PBS for the controls and received a second injection 240 min after the first injection. Values on the scale are in minutes. (B) *ptpn6* expression in control embryos was analyzed by qPCR 30, 120, and 240 min after the first insulin injection. RNA was extracted from larvae that had received injections of PBS or 100 nM insulin. Data (mean±S.E.M.) are combined from four biological replicates (*n*=3 larvae/group) and expressed relative to their respective PBS control, which is defined as 1. (C) Glucose dynamics were studied 30 and 240 min after administration of 100 nM insulin to confirm the effect of the first injection. A second injection with the same dose of insulin was administered 240 min after the first dose and glucose levels were analyzed 30 and 120 min later. Larvae that had received injections of PBS were used as controls and exhibited no significant changes in glucose levels during the experiment. Data (mean±S.E.M.) are combined from four biological replicates (*n*=5 larvae/group) *$P<0.05$. NS, no significant differences. A full colour version of this figure is available at http://dx.doi.org/10.1530/JOE-14-0178.

significant reduction in glucose levels 30 and 120 min after the second injection, confirming that abrogation of *ptpn6* improves the glycemic control of the larvae, therefore contributing to the prevention of the development of insulin resistance (Fig. 6 C).

Discussion

In the present report, we describe a non-obese animal model for the study of hyperinsulinemia-derived insulin resistance. Using a newly developed method to administer human insulin intravenously into developed zebrafish, we demonstrate not only that human insulin is functional in zebrafish, but also that these zebrafish larvae become insulin-resistant when high concentrations of human insulin are administered by injection. Our findings indicate that this effect is mediated by stimulation of *ptpn6* expression in the hyperinsulinemic scenario, leading concomitantly to immune suppression. Moreover, abrogation of *ptpn6* was found to counteract the effects of high plasma levels of insulin on the transcription of key genes of the insulin and leptin signaling pathways as well as of the innate immune response.

After injection of 100 nM human insulin into zebrafish larvae at 4 dpf, *pck1* transcription was rapidly inhibited and free glucose levels were significantly reduced at 15 min post injection, reaching normoglycemia again at 1 hpi, mimicking the effect in mammals (Sasaki *et al*. 1984, Barthel & Schmoll 2003, Seino *et al*. 2011). Next, the strong *pck1* downregulation observed at 4 hpi led us to propose the hypothesis that larvae that had received injections of insulin

Published by Bioscientifica Ltd.

could be experiencing insulin resistance caused by high plasma levels of insulin. In mammals, it is well established that insulin concentrations in the blood oscillate between post-absorptive periods, increasing again 4 h after each meal (Polonsky *et al.* 1988). In our case, a second insulin injection 4 h after the first injection did not cause transient hypoglycemia as observed after the first injection, instead we observed that these larvae showed transient hyperglycemia, consistent with other models of insulin resistance that present higher levels of plasma glucose (Shafrir 2010). However, it is worth mentioning that, despite not being statistically significant, at 2 hpi of the second insulin dose, glucose levels remained higher than in larvae that had received injections of PBS. This observation seems to contradict the observed downregulation of *pck1* and *g6pc* at 4 hpi, as these genes have been typically described as mediating a rate-limiting step of gluconeogenesis. In consequence, hyperglycemic states in pathologies characterized by poor glycemic control (e.g. type 2 diabetes, obesity, and metabolic syndrome) have been thought to be associated with upregulation of both *pck1* and *g6pc* expression. However, recent observations have challenged this paradigm. Samuel *et al.* (2009) demonstrated that expression of PEPCK and G6Pc was unaltered during fasting hyperglycemia using rodent models for diabetes. Moreover, in the same study, the authors showed that patients with type 2 diabetes did not exhibit any changes in hepatic PEPCK nor in G6Pc expression (Samuel *et al.* 2009). In addition, recently it has been shown that *Pepck* mutant mice exhibiting a 90% reduction in PEPCK protein levels only exhibit a 40% reduction in gluconeogenic flux (Burgess *et al.* 2007). Altogether, previous studies and the present data highlight the complex regulation of gluconeogenesis and indicate that further research focused on other less studied gluconeogenic genes (e.g. pyruvate carboxylase) should be carried out.

It is known that hyperinsulinemia can lead to insulin resistance in mammals by downregulating the mediators of the insulin signaling pathway (Kahn & Flier 2000), as shown by a number of *in vivo* studies where administration of high doses of insulin led to insulin resistance (Kobayashi & Olefsky 1978, Martin *et al.* 1983, Rizza *et al.* 1985). Supporting this notion, our data indicated that the transcription of genes coding for the key mediators of the insulin signaling pathway was inhibited, coinciding with the loss of insulin sensitivity and a decrease in Akt phosphorylation which is associated with insulin-resistant states (Tomas *et al.* 2002). Moreover, at this stage hyperinsulinemic larvae appeared to be immuno-suppressed at the transcriptional level, whereas the only

immune modulator showing an increased expression was *ptpn6*. In mammals and zebrafish, *ptpn6* has been reported to be a negative regulator of the immune response (Zhang *et al.* 2000, Tsui *et al.* 2006, Pao *et al.* 2007, An *et al.* 2008, Croker *et al.* 2008, Lorenz 2009, Kanwal *et al.* 2013) and a key determinant of development of insulin resistance and non-alcoholic fatty liver diseases (Xu *et al.* 2012, 2014*a*). We found that knocking down of *ptpn6* interfered with the inhibitory effect observed on key transcription factors and signal mediators of the NF-κB pathway as well as on various cytokines in larvae that had received injections of insulin. It is worth mentioning that, although *il1b* expression was reduced after insulin injection also in *ptpn6* knocked-down larvae, this is consistent with the observation that *il1b* expression was altered in *ptpn6* morphants at 5 dpf and onwards, but not at 4 dpf (Kanwal *et al.* 2013). Besides this, we also observed that some genes identified as playing a role in innate immunity, such as *mfap4*, *nos2b*, *cxcr3.1*, *cxcr4b*, and *irf5*, were upregulated at 4 hpi, and after *ptpn6* abrogation *mfap4* was still induced by insulin. We cannot rule out the possibility that other immune modulators involved in particular tissue-specific innate immune processes are under-represented in our data set because in our model we focussed on major changes at the whole-embryo level. Future studies on dissected organs or FACS-sorted cells using tissue-specific labeled transgenic lines will be helpful to improve our understanding of which mechanisms contribute to the development of this immune dysregulation.

Studying the effect of *ptpn6* abrogation on the insulin signaling pathway, we observed that morphant larvae administered insulin exhibited an increase in the expression of *insrb*, *irs1*, and *irs2* (though not significant in the case of *irs2*). These results are in agreement with data from *Ptpn6*-deficient (*Ptpn6*^me-v/me-v^) mice, which displayed

Figure 7
Model for hyperinsulinemia-induced immune suppression and insulin resistance via *ptpn6*. A full colour version of this figure is available at http://dx.doi.org/10.1530/JOE-14-0178.

increased tyrosine phosphorylation of INSR, IRS1, and IRS2 and an enhanced insulin sensitivity (Dubois *et al.* 2006). Supporting this notion, *ptpn6* morphants showed improved glycemic control, exhibiting hypoglycemia up to 2 h after administration of a second dose of insulin. This is consistent with the previous observations and confirms the central role of *ptpn6* in mediating hyperinsulinemia-derived insulin resistance in zebrafish.

In addition, key members of the leptin signaling pathway, namely *lepb*, are known to be regulated by nutritional factors in zebrafish as in its mammalian ortholog (Gorissen *et al.* 2009), and *lepr* appeared to be downregulated in insulin-resistant larvae while *ptpn6* abrogation was found to prevent this transcriptional inhibition.

Interestingly, it has been observed that stimulation of PTPN6 by insulin leads to JAK2 dephosphorylation, therefore interfering with the leptin signaling pathway (Kellerer *et al.* 2001). With these observations in mind, and knowing that animal models for insulin resistance with mutations in leptin or leptin receptor genes are immuno-suppressed it is tempting to propose the hypothesis that hyperinsulinemia may downregulate the insulin signaling pathway leading to insulin resistance via induction of *ptpn6*. Our results also indicate that the observed immuno-suppression may be due to a combination of factors, of which *ptpn6* is exerting its role as a negative immune regulator by inhibiting the leptin signaling pathway that eventually contributes to the observed immune dysregulation (Fig. 7).

These observations raise an interesting point for discussion. Leptin-deficient rodents used as models for insulin resistance are hyperinsulinemic, insulin-resistant, and immuno-compromised (Meade *et al.* 1979, Chandra 1980, Zhang *et al.* 1994, Lord *et al.* 1998, Howard *et al.* 1999). Importantly, these observations are, in part, opposite to the human scenario where obese individuals that develop insulin resistance exhibit high leptin levels and an induction of inflammation (Gregor & Hotamisligil 2011). To circumvent this, high-fat-diet-induced obese mice are also used as a model as they develop insulin resistance and hyperinsulinemia, but still there are some discrepancies with the human situation. One of the major issues we face when studying insulin resistance is that this is a state associated with a number of pathophysiologies, and in consequence a multi-factorial disease, making it difficult to study using animal models. In this light the main contribution of our model to the existing ones is that it complements them as it allows the study of insulin resistance in a non-obese animal, helping in this way to clarify the mechanisms by which insulin exerts its effect and more importantly how this can trigger insulin resistance.

In summary, in the present study, we provide a new tool for the study of insulin metabolism and insulin resistance. Taking advantage of the zebrafish model, in which we can easily obtain and handle large numbers of non-obese individuals with fully functional organs, we have demonstrated that zebrafish larvae are sensitive to human insulin. Importantly, we showed how i.v. injection of a high dose of insulin leads to insulin resistance and immune suppression. Moreover, we showed that modulating *ptpn6* expression interferes with the effects caused by hyperinsulinemia, preventing the downregulation of insulin and leptin signaling pathways and blocking the immune dysregulation. As mentioned by Kanwal *et al.* (2013), *ptpn6* regulation of transcription and its relation with immune suppression via the glucocorticoid pathway is still poorly understood. Future studies will be needed to elucidate the even more complex role that *ptpn6* plays regulating the transcription of the metabolic and immune signaling pathways mentioned in this study.

In conclusion, we present a new hyperinsulinemia animal model that complements the existing rodent models, allowing the study of insulin resistance in a non-obese state, and propose *ptpn6* as a key mediator triggering hyperinsulinemia-derived insulin resistance and immune suppression. This important connection between insulin regulation and the immune system can now be studied further in the various infection and cancer models that have been recently developed for zebrafish.

Author contribution statement
R M-J conceived the study, designed and performed experiments, analyzed the data, and wrote the paper. S J-R designed and performed experiments. S Y designed and performed experiments. H P S designed experiments, supervised the work, and wrote the paper. All authors assisted with editing of the manuscript and approved the final version.

References

Ali S, Champagne DL, Spaink HP & Richardson MK 2011 Zebrafish embryos and larvae: a new generation of disease models and drug screens. *Birth Defects Research. Part C, Embryo Today: Reviews* **93** 115–133. (doi:10.1002/bdrc.20206)

An HZ, Hou J, Zhou J, Zhao W, Xu HM, Zheng YJ, Yu YZ, Liu SX & Cao XT 2008 Phosphatase SHP-1 promotes TLR- and RIG-I-activated production of type I interferon by inhibiting the kinase IRAK1. *Nature Immunology* **9** 542–550. (doi:10.1038/ni.1604)

Araki E, Lipes MA, Patti ME, Bruning JC, Haag B III, Johnson RS & Kahn CR 1994 Alternative pathway of insulin signalling in mice with targeted disruption of the *IRS-1* gene. *Nature* **372** 186–190. (doi:10.1038/372186a0)

Barthel A & Schmoll D 2003 Novel concepts in insulin regulation of hepatic gluconeogenesis. *American Journal of Physiology. Endocrinology and Metabolism* **285** E685–E692. (doi:10.1152/ajpendo.00253.2003)

Benjamini Y & Hochberg Y 1995 Controlling the false discovery rate: a practical and powerful approach to multiple testing. *Journal of the Royal Statistical Society. Series B, Statistical Methodology* **57** 289–300.

Boura-Halfon S & Zick Y 2009 Phosphorylation of IRS proteins, insulin action, and insulin resistance. *American Journal of Physiology. Endocrinology and Metabolism* **296** E581–E591. (doi:10.1152/ajpendo.90437.2008)

Burgess SC, He TT, Yan Z, Lindner J, Sherry AD, Malloy CR, Browning JD & Magnuson MA 2007 Cytosolic phosphoenolpyruvate carboxykinase does not solely control the rate of hepatic gluconeogenesis in the intact mouse liver. *Cell Metabolism* **5** 313–320. (doi:10.1016/j.cmet.2007.03.004)

Chandra RK 1980 Cell-mediated immunity in genetically obese (C57BL/6J *ob/ob*) mice. *American Journal of Clinical Nutrition* **33** 13–16.

Croker BA, Lawson BR, Rutschmann S, Berger M, Eidenschenk C, Blasius AL, Moresco EMY, Sovath S, Cengia L, Shultz LD *et al.* 2008 Inflammation and autoimmunity caused by a SHP1 mutation depend on IL-1, MyD88, and a microbial trigger (vol 105, pg 15028, 2008). *PNAS* **105** 19561. (doi:10.1073/pnas.0806619105)

Driessen M, Kienhuis AS, Pennings JL, Pronk TE, van de Brandhof EJ, Roodbergen M, Spaink HP, van de Water B & van der Ven LT 2013 Exploring the zebrafish embryo as an alternative model for the evaluation of liver toxicity by histopathology and expression profiling. *Archives of Toxicology* **87** 807–823. (doi:10.1007/s00204-013-1039-z)

Dubois MJ, Bergeron S, Kim HJ, Dombrowski L, Perreault M, Fournes B, Faure R, Olivier M, Beauchemin N, Shulman GI *et al.* 2006 The SHP-1 protein tyrosine phosphatase negatively modulates glucose homeostasis. *Nature Medicine* **12** 549–556. (doi:10.1038/nm1397)

Elo B, Villano CM, Govorko D & White LA 2007 Larval zebrafish as a model for glucose metabolism: expression of phosphoenolpyruvate carboxy-kinase as a marker for exposure to anti-diabetic compounds. *Journal of Molecular Endocrinology* **38** 433–440. (doi:10.1677/JME-06-0037)

Ginsberg BH, Kahn CR, Roth J & De Meyts P 1976 Insulin-induced dissociation of its receptor into subunits: possible molecular con-comitant of negative cooperativity. *Biochemical and Biophysical Research Communications* **73** 1068–1074. (doi:10.1016/0006-291X(76)90232-1)

Gorissen M, Bernier NJ, Nabuurs SB, Flik G & Huising MO 2009 Two divergent leptin paralogues in zebrafish (*Danio rerio*) that originate early in teleostean evolution. *Journal of Endocrinology* **201** 329–339. (doi:10.1677/JOE-09-0034)

Gregor MF & Hotamisligil GS 2011 Inflammatory mechanisms in obesity. *Annual Review of Immunology* **29** 415–445. (doi:10.1146/annurev-immunol-031210-101322)

Harano Y, Suzuki M, Koyama Y, Kanda M, Yasuda S, Suzuki K & Takamizawa I 2002 Multifactorial insulin resistance and clinical impact in hypertension and cardiovascular diseases. *Journal of Diabetes and its Complications* **16** 19–23. (doi:10.1016/S1056-8727(01)00192-1)

Howard JK, Lord GM, Matarese G, Vendetti S, Ghatei MA, Ritter MA, Lechler RI & Bloom SR 1999 Leptin protects mice from starvation-induced lymphoid atrophy and increases thymic cellularity in *ob/ob* mice. *Journal of Clinical Investigation* **104** 1051–1059. (doi:10.1172/JCI6762)

Jiang M, Zhang Y, Liu M, Lan MS, Fei J, Fan W, Gao X & Lu D 2011 Hypermethylation of hepatic glucokinase and L-type pyruvate kinase promoters in high-fat diet-induced obese rats. *Endocrinology* **152** 1284–1289. (doi:10.1210/en.2010-1162)

Jurczyk A, Roy N, Bajwa R, Gut P, Lipson K, Yang CX, Covassin L, Racki WJ, Rossini AA, Phillips N *et al.* 2011 Dynamic glucoregulation and mammalian-like responses to metabolic and developmental disruption in zebrafish. *General and Comparative Endocrinology* **170** 334–345. (doi:10.1016/j.ygcen.2010.10.010)

Kahn SE 2003 The relative contributions of insulin resistance and β-cell dysfunction to the pathophysiology of type 2 diabetes. *Diabetologia* **46** 3–19. (doi:10.1007/s00125-003-1190-9)

Kahn BB & Flier JS 2000 Obesity and insulin resistance. *Journal of Clinical Investigation* **106** 473–481. (doi:10.1172/JCI10842)

Kanwal Z, Zakrzewska A, den Hertog J, Spaink HP, Schaaf MJ & Meijer AH 2013 Deficiency in hematopoietic phosphatase Ptpn6/Shp1 hyper-activates the innate immune system and impairs control of bacterial infections in zebrafish embryos. *Journal of Immunology* **190** 1631–1645. (doi:10.4049/jimmunol.1200551)

Kellerer M, Lammers R, Fritsche A, Strack V, Machicao F, Borboni P, Ullrich A & Haring HU 2001 Insulin inhibits leptin receptor signalling in HEK293 cells at the level of janus kinase 2: a potential mechanism for hyperinsulinaemia-associated leptin resistance. *Diabetologia* **44** 1125–1132. (doi:10.1007/s001250100614)

Kimmel CB, Ballard WW, Kimmel SR, Ullmann B & Schilling TF 1995 Stages of embryonic development of the zebrafish. *Developmental Dynamics* **203** 253–310. (doi:10.1002/aja.1002030302)

Kobayashi M & Olefsky JM 1978 Effect of experimental hyperinsulinemia on insulin binding and glucose transport in isolated rat adipocytes. *American Journal of Physiology* **235** E53–E62.

Lieschke GJ & Currie PD 2007 Animal models of human disease: zebrafish swim into view. *Nature Reviews. Genetics* **8** 353–367. (doi:10.1038/nrg2091)

Lin Y & Sun Z 2010 Current views on type 2 diabetes. *Journal of Endocrinology* **204** 1–11. (doi:10.1677/JOE-09-0260)

Liu S & Leach SD 2011 Zebrafish models for cancer. *Annual Review of Pathology* **6** 71–93. (doi:10.1146/annurev-pathol-011110-130330)

Lord GM, Matarese G, Howard JK, Baker RJ, Bloom SR & Lechler RI 1998 Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression. *Nature* **394** 897–901. (doi:10.1038/29795)

Lorenz U 2009 SHP-1 and SHP-2 in T cells: two phosphatases functioning at many levels. *Immunological Reviews* **228** 342–359. (doi:10.1111/j.1600-065X.2008.00760.x)

Martin C, Desai KS & Steiner G 1983 Receptor and postreceptor insulin resistance induced by *in vivo* hyperinsulinemia. *Canadian Journal of Physiology and Pharmacology* **61** 802–807. (doi:10.1139/y83-123)

Meade CJ, Sheena J & Mertin J 1979 Effects of the obese (*ob/ob*) genotype on spleen cell immune function. *International Archives of Allergy and Applied Immunology* **58** 121–127. (doi:10.1159/000232183)

Meijer AH & Spaink HP 2011 Host–pathogen interactions made transparent with the zebrafish model. *Current Drug Targets* **12** 1000–1017. (doi:10.2174/138945011795677809)

Meijer AH, van der Vaart M & Spaink HP 2014 Real-time imaging and genetic dissection of host-microbe interactions in zebrafish. *Cellular Microbiology* **16** 39–49. (doi:10.1111/cmi.12236)

O'Brien RM & Granner DK 1990 PEPCK gene as model of inhibitory effects of insulin on gene transcription. *Diabetes Care* **13** 327–339. (doi:10.2337/diacare.13.3.327)

Pao LI, Badour K, Siminovitch KA & Neel BG 2007 Nonreceptor protein-tyrosine phosphatases in immune cell signaling. *Annual Review of Immunology* **25** 473–523. (doi:10.1146/annurev.immunol.23.021704.115647)

Patti ME & Kahn CR 1996 Lessons from transgenic and knockout animals about noninsulin-dependent diabetes mellitus. *Trends in Endocrinology and Metabolism* **7** 311–319. (doi:10.1016/S1043-2760(96)00154-3)

Polonsky KS, Given BD & Van Cauter E 1988 Twenty-four-hour profiles and pulsatile patterns of insulin secretion in normal and obese subjects. *Journal of Clinical Investigation* **81** 442–448. (doi:10.1172/JCI113339)

Rizza RA, Mandarino LJ, Genest J, Baker BA & Gerich JE 1985 Production of insulin resistance by hyperinsulinaemia in man. *Diabetologia* **28** 70–75. (doi:10.1007/BF00279918)

Samuel VT, Beddow SA, Iwasaki T, Zhang XM, Chu X, Still CD, Gerhard GS & Shulman GI 2009 Fasting hyperglycemia is not associated with increased expression of PEPCK or G6Pc in patients with type 2 diabetes. *PNAS* **106** 12121–12126. (doi:10.1073/pnas.0812547106)

Santoriello C & Zon LI 2012 Hooked! Modeling human disease in zebrafish. *Journal of Clinical Investigation* **122** 2337–2343. (doi:10.1172/JCI60434)

Sasaki K, Cripe TP, Koch SR, Andreone TL, Petersen DD, Beale EG & Granner DK 1984 Multihormonal regulation of phosphoenolpyruvate carboxykinase gene transcription. The dominant role of insulin. *Journal of Biological Chemistry* **259** 15242–15251.

Schlegel A & Stainier DYR 2007 Lessons from "lower" organisms: what worms, flies, and zebrafish can teach us about human energy metabolism. *PLoS Genetics* **3** 2037–2048. (doi:10.1371/journal.pgen.0030199)

Seino S, Shibasaki T & Minami K 2011 Dynamics of insulin secretion and the clinical implications for obesity and diabetes. *Journal of Clinical Investigation* **121** 2118–2125. (doi:10.1172/JCI45680)

Sell H, Bluher M, Kloting N, Schlich R, Willems M, Ruppe F, Knoefel WT, Dietrich A, Fielding BA, Arner P et al. 2013 Adipose dipeptidyl peptidase-4 and obesity: correlation with insulin resistance and depot-specific release from adipose tissue *in vivo* and *in vitro*. *Diabetes Care* **36** 4083–4090. (doi:10.2337/dc13-0496)

Seth A, Stemple DL & Barroso I 2013 The emerging use of zebrafish to model metabolic disease. *Disease Models & Mechanisms* **6** 1080–1088. (doi:10.1242/dmm.011346)

Shafrir E 2010 Contribution of animal models to the research of the causes of diabetes. *World Journal of Diabetes* **1** 137–140. (doi:10.4239/wjd.v1.i5.137)

Shanik MH, Xu Y, Skrha J, Dankner R, Zick Y & Roth J 2008 Insulin resistance and hyperinsulinemia: is hyperinsulinemia the cart or the horse? *Diabetes Care* **31**(Suppl 2) S262–S268. (doi:10.2337/dc08-s264)

Steinberger J & Daniels SR 2003 Obesity, insulin resistance, diabetes, and cardiovascular risk in children: an American Heart Association scientific statement from the Atherosclerosis, Hypertension, and Obesity in the Young Committee (Council on Cardiovascular Disease in the Young) and the Diabetes Committee (Council on Nutrition, Physical Activity, and Metabolism). *Circulation* **107** 1448–1453. (doi:10.1161/01.CIR.0000060923.07573.F2)

Tahara Y, Otsuka M, Fuse Y, Hirao A & Shibata S 2011 Refeeding after fasting elicits insulin-dependent regulation of *Per2* and *Rev-erbα* with shifts in the liver clock. *Journal of Biological Rhythms* **26** 230–240. (doi:10.1177/0748730411405958)

Tamemoto H, Kadowaki T, Tobe K, Yagi T, Sakura H, Hayakawa T, Terauchi Y, Ueki K, Kaburagi Y, Satoh S et al. 1994 Insulin resistance and growth retardation in mice lacking insulin receptor substrate-1. *Nature* **372** 182–186. (doi:10.1038/372182a0)

Tomas E, Lin YS, Dagher Z, Saha A, Luo ZJ, Ido Y & Ruderman NB 2002 Hyperglycemia and insulin resistance: possible mechanisms. *Annals of the New York Academy of Sciences* **967** 43–51. (doi:10.1111/j.1749-6632.2002.tb04262.x)

Tsui FW, Martin A, Wang J & Tsui HW 2006 Investigations into the regulation and function of the SH2 domain-containing protein-tyrosine phosphatase, SHP-1. *Immunologic Research* **35** 127–136. (doi:10.1385/IR:35:1:127)

van der Vaart M, Spaink HP & Meijer AH 2012 Pathogen recognition and activation of the innate immune response in zebrafish. *Advances in Hematology* **2012** 159807. (doi:10.1155/2012/159807)

Wang J, Obici S, Morgan K, Barzilai N, Feng Z & Rossetti L 2001 Overfeeding rapidly induces leptin and insulin resistance. *Diabetes* **50** 2786–2791. (doi:10.2337/diabetes.50.12.2786)

Westerfield M 2000 In *The Zebrafish Book: A Guide for the Laboratory Use of Zebrafish (Danio rerio)*, 4th edn, Eugene, OR: University of Oregon Press.

Wild SH & Byrne CD 2006 The global burden of the metabolic syndrome and its consequences for diabetes and cardiovascular disease. In *The Metabolic Syndrome*, pp 1–41. Eds CD Byrne & SH Wild. Chichester: John Wiley & Sons, Ltd. (doi:10.1002/0470025131.ch1)

Withers DJ, Gutierrez JS, Towery H, Burks DJ, Ren JM, Previs S, Zhang Y, Bernal D, Pons S, Shulman GI et al. 1998 Disruption of IRS-2 causes type 2 diabetes in mice. *Nature* **391** 900–904. (doi:10.1038/36116)

Xu E, Charbonneau A, Rolland Y, Bellmann K, Pao L, Siminovitch KA, Neel BG, Beauchemin N & Marette A 2012 Hepatocyte-specific *Ptpn6* deletion protects from obesity-linked hepatic insulin resistance. *Diabetes* **61** 1949–1958. (doi:10.2337/db11-1502)

Xu E, Forest M-P, Schwab M, Avramoglu RK, St-Amand E, Caron AZ, Bellmann K, Shum M, Voisin G, Paquet M et al. 2014a Hepatocyte-specific *Ptpn6* deletion promotes hepatic lipid accretion, but reduces NAFLD in diet-induced obesity: potential role of PPARγ. *Hepatology* **59** 1803–1815. (doi:10.1002/hep.26957)

Xu E, Schwab M & Marette A 2014b Role of protein tyrosine phosphatases in the modulation of insulin signaling and their implication in the pathogenesis of obesity-linked insulin resistance. *Reviews in Endocrine & Metabolic Disorders* **15** 79–97. (doi:10.1007/s11154-013-9282-4)

Yi TL, Cleveland JL & Ihle JN 1992 Protein tyrosine phosphatase containing SH2 domains – characterization, preferential expression in hemato-poietic-cells, and localization to human-chromosome 12p12–P13. *Molecular and Cellular Biology* **12** 836–846. (doi:10.1128/MCB.12.2.836)

Zhang Y, Proenca R, Maffei M, Barone M, Leopold L & Friedman JM 1994 Positional cloning of the mouse *obese* gene and its human homologue. *Nature* **372** 425–432. (doi:10.1038/372425a0)

Zhang J, Somani AK & Siminovitch KA 2000 Roles of the SHP-1 tyrosine phosphatase in the negative regulation of cell signalling. *Seminars in Immunology* **12** 361–378. (doi:10.1006/smim.2000.0223)

Published by Bioscientifica Ltd.